BR112012024796A2 - inibidores de integrase macrocíclicos - Google Patents

inibidores de integrase macrocíclicos

Info

Publication number
BR112012024796A2
BR112012024796A2 BR112012024796A BR112012024796A BR112012024796A2 BR 112012024796 A2 BR112012024796 A2 BR 112012024796A2 BR 112012024796 A BR112012024796 A BR 112012024796A BR 112012024796 A BR112012024796 A BR 112012024796A BR 112012024796 A2 BR112012024796 A2 BR 112012024796A2
Authority
BR
Brazil
Prior art keywords
integrase inhibitors
macrocyclic
macrocyclic integrase
inhibitors
solvates
Prior art date
Application number
BR112012024796A
Other languages
English (en)
Inventor
Jean-François Bonfanti
Johannes Wilhelmus J Thuring
Original Assignee
Janssen R&D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen R&D Ireland filed Critical Janssen R&D Ireland
Publication of BR112012024796A2 publication Critical patent/BR112012024796A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

inibidores de integrase macrocíclicos. a presente invenção refere-se a um composto tendo a fórmula (i) e sais ou solvatos farmaceuticamente aceitáveis do mesmo, suas formulações farmacêuticas e uso como inibidores de hiv.
BR112012024796A 2010-04-02 2011-04-01 inibidores de integrase macrocíclicos BR112012024796A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10159060 2010-04-02
PCT/EP2011/055077 WO2011121105A1 (en) 2010-04-02 2011-04-01 Macrocyclic integrase inhibitors

Publications (1)

Publication Number Publication Date
BR112012024796A2 true BR112012024796A2 (pt) 2016-06-07

Family

ID=42135906

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012024796A BR112012024796A2 (pt) 2010-04-02 2011-04-01 inibidores de integrase macrocíclicos

Country Status (7)

Country Link
US (1) US8716293B2 (pt)
EP (1) EP2552923B1 (pt)
JP (1) JP5739517B2 (pt)
CN (1) CN102958935B (pt)
BR (1) BR112012024796A2 (pt)
RU (1) RU2567385C2 (pt)
WO (1) WO2011121105A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906929B2 (en) * 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
EP2986291B1 (en) 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
HUE036384T2 (hu) 2013-05-17 2018-07-30 Merck Sharp & Dohme Fúzionált triciklusos heterociklikus vegyületek mint HIV integráz inhibitorok
EP3008044B1 (en) 2013-06-13 2018-11-21 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
MD4794B1 (ro) 2013-09-27 2022-02-28 Merck Sharp & Dohme Corp Derivaţi de chinolizină substituiţi utili ca inhibitori de integrază HIV
CN105693727B (zh) * 2014-11-27 2018-10-16 上海合全药业股份有限公司 8-（叔丁氧羰基）-6,7,8,9-四氢-5-氢-咪唑[1,5-a][1,4]二氮杂-6-羧酸的合成方法
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
EP3377066B1 (en) 2015-11-17 2021-04-07 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
WO2017106071A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
BR112019011074B1 (pt) 2016-12-02 2021-01-19 Merck Sharp & Dohme Corp. Compostos heterocíclicos tricíclicos inibidores de hiv integrase, composição que oscompreende e uso dos mesmos
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
EP3573984A4 (en) 2017-01-26 2020-07-29 Merck Sharp & Dohme Corp. USEFUL SUBSTITUTE QUINOLIZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS
TWI745900B (zh) 2019-03-22 2021-11-11 美商基利科學股份有限公司 橋鍵聯三環胺甲醯吡啶酮化合物及其醫藥用途
PE20221569A1 (es) 2020-02-24 2022-10-06 Gilead Sciences Inc Compuestos tetraciclicos para el tratamiento de infecciones por vih
CN110981757A (zh) * 2020-02-26 2020-04-10 海南师范大学 一种高效的4-（氯磺酰基）-1-新戊酸丁酯的合成方法
ES2968058T3 (es) 2021-01-19 2024-05-07 Gilead Sciences Inc Compuestos de piridotriazina sustituidos y usos de los mismos
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT66531A (en) * 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
WO2002020930A1 (en) 2000-09-05 2002-03-14 Crittall Windows Limited Window frames
AU1152702A (en) 2000-10-12 2002-04-22 Merck & Co Inc Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
ES2274913T3 (es) 2000-10-12 2007-06-01 MERCK & CO., INC. Aza y poliaza-naftalenil carboxamidas utiles como inhibidores de vih integrada.
US20050010048A1 (en) 2000-10-12 2005-01-13 Linghang Zhuang Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors
US6919351B2 (en) 2000-10-12 2005-07-19 Merck & Co., Inc. Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors
AU2003301439A1 (en) 2002-10-16 2004-05-04 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
EP3406596A1 (en) 2002-11-20 2018-11-28 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
EP1578748B1 (en) 2002-12-27 2010-09-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
US6890942B2 (en) 2003-05-16 2005-05-10 Bristol-Myers Squibb Company Acyl sulfonamides as inhibitors of HIV integrase
CA2537325A1 (en) 2003-09-19 2005-03-31 Gilead Sciences, Inc. Aza-quinolinol phosphonate integrase inhibitor compounds
CN1870896A (zh) * 2003-10-20 2006-11-29 默克公司 用作hiv整合酶抑制剂的羟基吡啶并吡咯并吡嗪二酮化合物
CA2557926A1 (en) 2004-03-09 2005-09-22 Monica Donghi Hiv integrase inhibitors
WO2005110415A1 (en) * 2004-05-07 2005-11-24 Merck & Co., Inc. Hiv integrase inhibitors
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
DK2465580T3 (en) 2005-04-28 2014-03-10 Viiv Healthcare Co POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVES WITH HIV INTEGRASE INHIBITIVE ACTIVITY
TW200811153A (en) 2006-06-23 2008-03-01 Japan Tobacco Inc 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor

Also Published As

Publication number Publication date
EP2552923B1 (en) 2014-03-26
RU2012146777A (ru) 2014-05-10
CN102958935A (zh) 2013-03-06
JP2013523695A (ja) 2013-06-17
US20130035341A1 (en) 2013-02-07
CN102958935B (zh) 2015-12-09
US8716293B2 (en) 2014-05-06
RU2567385C2 (ru) 2015-11-10
JP5739517B2 (ja) 2015-06-24
EP2552923A1 (en) 2013-02-06
WO2011121105A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
BR112012024796A2 (pt) inibidores de integrase macrocíclicos
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
CO6741203A2 (es) Derivados de biciclo[3,2,1]octilamida y sus usos
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CO6460772A2 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CO6571861A2 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina y su uso como inhibidor de la integrasa del vih
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
EA201270540A1 (ru) Макроциклические ингибиторы интегразы
BR112015000704A2 (pt) imidazotriazinacarbonitrilas úteis como inibidores de quinase
NI201400108A (es) Compuestos de heterociclilo
MA34069B1 (fr) Dérivés de n-(imidazopyrimidin-7-yl)hétéroarylamide et leur utilisation comme inhibiteurs de pde10a)
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
TR201909152T4 (tr) Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımı.
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
GEP201606555B (en) Compounds and compositions for modulating egfr activity
BRPI1008498A2 (pt) Composto, prodroga do composto, medicamento, e, uso de um composto.
EA201390885A1 (ru) Азаиндолы в качестве противовирусных агентов против респираторного синцитиального вируса
BR112014019171A8 (pt) Composições intranasais de dexdetomida e seus métodos de uso
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
GEP201706698B (en) Inhibitors of influenza viruses replication
CY1121999T1 (el) Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης
CY1117792T1 (el) Ανταγωνιστες toy trpv4
BRPI0821255A2 (pt) Derivados de espiroindolinona
UY33075A (es) Derivados de ciclohexano y usos de los mismos
MY187718A (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2508 DE 29-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.